secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEXGEL, INC. (NXGL)
CIK:        0001468929
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001493152-24-018955
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NEXGEL Q1 revenue $1.27M (+104% YoY); net loss $905K vs $807K YoY
-----------------------------------------------------------------

- Revenue increased 104% to $1.27M, driven by contract manufacturing (+58%) and branded products (+178%).
- Gross profit turned positive to $277K from a loss of $57K YoY; gross margin 21.9% vs negative 9.2%.
- Net loss widened to $905K from $807K; SG&A up 43.8% to $1.1M on higher advertising and consulting costs.
- Cash balance $2.4M as of March 31, 2024, including ~$1M insider-led registered direct offering.
- Capacity expansion in Texas nearly complete; product launches with Abbvie and European market entry expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468929/000149315224018955/0001493152-24-018955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468929/000149315224018955/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer